 |
 
|
|
|
|
Wednesday, September 29, 2010
|
07.50
|
BREAKFAST BUFFET at the Klosterwirt |
|
08.30
|
L-23 Myelofibrosis: SPECIAL: Molecular and cell biological aspects |
|
|
Hans KREIPE, Hannover, Germany - confirmed |
VIII. Organ Fibrosis: Lung
|
09.10
|
L-24 Lung fibrosis: OVERVIEW |
|
|
Borna MEHRAD, Virginia, USA - confirmed |
|
09.50
|
L-25 Lung fibrosis: SPECIAL
ADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury
|
|
|
Victor J.THANNICKAL, Birmingham, USA - confirmed
|
IX. Fibrosis as a Reversible Process
|
11.00
|
L-26 |
|
|
Kenneth LIPSON, San Francisco, CA; USA - confirmed |
|
11.40
|
L-27 Antifibrosis: to reverse the irreversible. |
|
|
Y SCHOENFELD, Tel Aviv, ISRAEL - confirmed |
|
12.20
|
L-28 Reversibility of Myelofibrosis through stem cell transplantation |
|
|
Nikolaus KRÖGER, Hamburg, GERMANY - confirmed |
|
14.00
|
L-29 Reversibility of Hepatic Fibrosis |
|
|
Antonella PELLICORO, Edinburgh, UK - confirmed |
XI. Antifibrotic Therapies
|
14.40
|
L-30 Reducing inflammatory processes associated with fibrosis: Role of monocyte subsets |
|
|
Frank TACKE, Aachen, Germany - confirmed
|
|
15.50
|
L-31 Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway
|
|
|
Shreyasi DAS, La Jolla, USA - confirmed |
|
16.30
|
L-32 Reducing biosynthesis and processing of collagens: Inhibition of Collagen fibril formation
|
|
|
Andrzej FERTALA, Philadelphia, USA - confirmed |
|
17.10
|
L-33 Herbogenomics: From Traditional Chinese Medicine to novel therapeutics |
|
|
Y. James KANG, Louisville, USA - confirmed |
|
